Found 60 Vision Loss trials
A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A phase 3 multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and a low residual -cell function
The objective of this clinical trial is to assess whether ladarixin treatment is effective in preserving -cell function and delaying the progression of T1D in adolescent and adult patients. The safety of ladarixin in the specific clinical setting will be also evaluated.
PROTECT- study of the efficacy and safety of sparsentan for the treatment of Immunoglobulin A (IgAN) nephropathy
Phase 3
Immunoglobulin A nephropathy (IgAN) is a rare disease that affects the kidneys, mostly in teens and adults. Kidneys are important to your health because they filter waste materials such as salts, toxins and water out of the blood. The waste is passed out of your body as urine (pee). IgAN …
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS-IgAN)
Phase 3
This study will use a new investigational study drug called OMS721 in people with Immunoglobulin A (IgA) Nephropathy. This kidney disease produces abnormal amounts of a protein called IgA in the kidney that damage the filtering units or glomeruli. Glomeruli are tiny filtering units in the kidney that remove excess …
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)
Phase 3
This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events (MACE) in subjects with Acute Coronary Syndrome (diagnosed with STEMI or NSTEMI), who are receiving evidence-based medical therapy.
A Single-blind Phase 2 Multi-center Randomized Study to Assess Safety Tolerability Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients with Hepatorenal Syndrome-Acute Kidney Injury
A Single-blind, Phase 2, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients with Hepatorenal Syndrome-Acute Kidney Injury
Intercept 787-201
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects with Severe Alcohol-Associated Hepatitis.
Glisten
A two-part, randomized, placebo controlled, double blind, multicenter, Phase 3 study to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants with primary biliary cholangitis (PBC).
A double-blind randomized placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis
This Phase 3, double-blind, randomized, placebo-controlled, parallel-group, multi-center, international study will assess the efficacy, safety and tolerability of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis (IPA).
A5394: Safety Tolerability and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants with Both Chronic Hepatitis B and HIV
A5394 is a phase II, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and efficacy of 24 weeks of treatment with Selgantolimod (SLGN). Intensive PK sampling will be conducted in the first 12 participants who enroll into the study.
Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia
This is a Phase II, double-blind, sham controlled, randomized, crossover, multisite clinical trial investigating the effectiveness of transcranial direct current stimulation (tDCS) coupled with naming and spelling therapy (NASP) to improve language in people with primary progressive aphasia (PPA).
